$405 Profit
VTVTShort Stock
TimLento

Shs Float 82.02M. $2.10 to $4.23. vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes. Broker ~ https://bit.ly/2UZo8oX Scanner ~ https://bit.ly/TS87emd

1
200

DatePrice
Entry2/10/20203.9725
Exit2/10/20203.77
  • Total Views241
  • Position Size2,000
  • Percentage5.1%
Proof
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only:
trisjace
trisjaceMay 17, 20 11:11 AM

Love your trading posts! Very detailed, educational, and informative!

Join now or log in to leave a comment